A comprehensive view of Neurological / Cognitive Health. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

GlobalData: Eli Lilly set to reshape pharmaceutical landscape with obesity and Alzheimer's treatments, Mounjaro and donanemab; both drugs poised to beat market expectations, with Mounjaro's sales poised to reach US$34B in 2029, more than double Wegovy's
Published: April 17, 2024 by GlobalData Plc
Phase 3 study of Roche's OCREVUS subcutaneous injection shows near-complete suppression of multiple sclerosis relapse activity and lesions; approval anticipated from FDA and EMA in 2024
Published: April 17, 2024 by F. Hoffmann-La Roche Ltd. (Roche)
Sage Therapeutics announces topline results from Phase 2 PRECEDENT Study of Dalzanemdor SAGE-718 in the treatment of mild cognitive impairment in Parkinson’s disease
Published: April 17, 2024 by Sage Therapeutics
US Patent Issued to Boston Scientific Neuromodulation on April 16 for "Neuromodulation for neuroinflammation treatments with parameters controlled using biomarkers" (Texas, California Inventors)
Published: April 17, 2024 by U.S. Fed News
Sanofi's frexalimab shows high efficacy in 48-week Phase 2 trial for multiple sclerosis, with an annualized relapse rate of 0.04 for high-dose variants; Phase 3 studies have begun for both relapsing and non-relapsing secondary progressive MS
Published: April 17, 2024 by Sanofi SA

Ask us about our R&D/Patents market view

Trending Chart

Interactive chart with headline count